Your end-to-end CDMO partner for your viral vector projects Exemplaire
Learn more about us
WHO WE ARE?
We are a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of gene therapies, oncolytic viruses and vaccine candidates. Our teams of experts based on our 3 sites, in Europe and in the US, are devoted to support innovative projects and help to reduce overall timelines and costs.
Our mission is to provide GMP viral vectors from early-stage to market, contributing to the success of our clients’ immunotherapy and gene therapy innovations.
We offer a broad range of viral vectors, including AAV, LVV, MVA, Poxvirus, Vaccinia, Measles, and more.
Our CDMO services include manufacturing of bulk drug substance, fill-finish of drug products, process and assay development, bioanalytical testing and regulatory support.
We place the client at the heart of everything we do. We implement strategies to achieve Best-class Customer Experience. A team of experts is dedicated to your project to provide you the best innovative solutions adapted to your needs in order to meet your expectations.
1994
first viral vector facility in Europe
3 facilities (France & USA)
~320 employees
>25 years of experience
in viral vectors (manufacturing)
Fill & up to 10 000 vials/batch
OUR HISTORY
ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of oncolytic viruses, gene therapies, and vaccine candidates based on viral vectors.
We are grounded in the Mérieux family’s legacy of biology and vaccine expertise, dating back to 1897.
As a pioneer, we have been developing and producing virus vector since 1990s. We started with Pox Virus, MVA, Vaccinia and oncolytic viruses to support our clients’ clinical trials with the final goal of fighting against smallpox and several types of cancer.
We have continuously added new viruses within our portfolio, including manufacturing of AAVs in 2016 through adherent and suspension processes. Based on this strong expertise in virology and cell culture, in 2022 we decided to develop our high predictable yield and versatile AAV platform to manufacture different serotypes.
More than ever, our vision is to contribute to a long-term public health vision where Bio-Industry has a central role for a healthier world.
1961
1968
1985
2001
2004
2011
2014
2016
2018
1961
Bionetic Research Laboratory est créé
1968
Acquisition par Litton Industries. Activités élargies aux rétrovirus et à la recherche contre le cancer
1985
Organon Teknika acquiert des actifs de R&D et de diagnostic, et renomme la société ABL
2001
bioMérieux acquiert ABL, qui devient une société du groupe Institut Mérieux
2004
ABL devient une société dérivée de bioMérieux, une société sœur, sous l’égide de l’Institut Mérieux
2011
ABL établi son siège social à Rockville, MD (Etats Unis)
2014
ABL acquiert Platine Pharma à Lyon and construit les laboratoires de test GCLP
2016
Création de la première entité d’ABL entity en France, à travers l’acquisition des actifs de production de Transgene à Strasbourg*
* Expansion des capacités d’ABL grâce à l’usine de fabrication de vecteurs viraux, certifiée GMP en 1995.
2018
Création de la seconde entité d’ABL entity en France, à travers l’acquisition de la plateforme innovante Accinov à Lyon
Today, ABL is fully owned by Institut Mérieux.
OUR MISSION & VISION
OUR MISSION: By accelerating our Customer’s life-saving innovations, ABL is contributing to a long-term public health vision where Bio-Industry has a central role for a healthier world.
OUR VISION: Become a leading global biomanufacturing CDMO trusted to deliver innovation and excellence. We empower people. We foster an entrepreneurial culture. We commit to sustainability.
WHAT DO WE OFFER?
ABL
Your solution provider
Developing and manufacturing viral vectors for over 25 years
Read more
We had our first facility GMP certified in 1995.
We produce a wide range of viral vectors: Vaccinia, MVA, Adeno, Measles, ORF, Arenavirus, AAV and others.
From the early clinical phases, we consider the cost to the patients.
Innovative treatments must be affordable to respond to unmet medical needs.
To help you bring sustainable solutions to the market, we do not hesitate to test emerging innovations and cutting-edge technologies.
Dedicated project management
Read more
An open and mutual collaboration with you and your team is key to meet your project objectives and overcome technical challenges.
For each project, we assign a dedicated Project Manager (PM) who will be your main point of contact throughout the collaboration.
The PM supervises each step of the process, from project kick off, technical meetings to daily management of the multidisciplinary teams working on your project.
To provide you with the best quality services, we ensure continuous training and improvement of our ways of working.
Effective quality control capabilities essential for your success
Read more
Within an international competitive environment, right first time and in due time is critical for a successful submission, approval and launching.
In close collaboration with your team we will design and execute a detailed and robust process and analytical development plan, phase appropriate, accordingly to your product specification and overall project milestones. You can rely on our extensive experience with dossier submission and interaction with major health authorities. We generate all the necessary data package to make your discussion with health authorities a success.
Flexibility within our contracts
Read more
Our contracts are based on milestones achievements.
We will facilitate tech transfer to another site if required. We acknowledge that you need flexibility to support a potential licensing out strategy.
Transparency, including on pricing revision indexation, is a key word at ABL Fast into Clinic: ABL is organized to implement a lean and seamless process to minimize the timing from RFP reception to delivery of first material you need, without compromising with the quality.
Customer centricity
Read more
You are at the center of our strategic decisions.
We offer you an hollistic approach, including solutions beyond the product manufacturing.
You can rely on our skilled and passionate teams to make your CMC journey easier and faster to market.
Talented teams to deliver the highest level of services
Read more
People are key assets within ABL, we consider that skills and experience of our collaborators are critical to bring value to your projects.
We foster diversity and creativity.
We encourage the continuous improvement through:
The versatility and adaptability of our manufacturing team to meet timelines without compromising quality.
Cross fertilization between our sites to implement the best practices and to organize seamless and efficient tech transfer.
Continuous training of our technicians and engineers through partnership with recognized universities having development and manufacturing fab-labs.